This week, cardiac monitoring firm AngelMed announced its new name; Tempus nabbed FDA approval for its tumor profiling test; and iRhythm revealed that it’s been subpoenaed by the US Department of Justice.
Wearable cardiac monitor company iRhythm Technologies, Inc. is facing a subpoena from the US Department of Justice’s Consumer Protection Branch, the company announced during a 4 May earnings call. This is the third time federal investigators have subpoenaed the company in less than two years.
Company officials said that iRhythm is cooperating with the subpoena, but declined to speculate on the nature or timing of the inquiry. But Boston Scientific announced in April that its...
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.
